Sou Hu Cai Jing·2026-01-29 09:49Core Viewpoint - Nocera Biopharma (09969.HK) is expected to achieve significant revenue growth and profitability in 2025, marking a turnaround from previous losses [1] Financial Performance - The company anticipates total revenue of approximately RMB 2.365 billion for 2025, representing a growth of around 134% compared to the previous year [1] - Nocera Biopharma expects to report a net profit attributable to shareholders of approximately RMB 633 million, an increase of about RMB 1.074 billion compared to the previous year [1] - The projected net profit, excluding non-recurring items, is expected to be around RMB 534 million, which is an increase of approximately RMB 974 million year-on-year [1] Stock Performance and Analyst Ratings - As of January 29, 2026, Nocera Biopharma's stock closed at HKD 11.62, down 0.43%, with a trading volume of 3.5789 million shares and a turnover of HKD 41.54 million [1] - The majority of investment banks have a "buy" rating on the stock, with three firms issuing buy ratings in the last 90 days and a target average price of HKD 17.9 [1] - Guoyuan International Holdings has given a buy rating with a target price of HKD 16.81 [1] Market Position - Nocera Biopharma has a market capitalization of HKD 17.433 billion and ranks 9th in the biopharmaceutical industry [1]